Search results for "Mab"
Article
Improving Process-Scale Chromatography
The development of new resin chemistries including enhancements to Protein A for monoclonal antibody (mAb) capture, increasing use of automation, implementation of single-use technologies, and explora…
Article
USP Publishes Monoclonal Antibody Guidelines
USP standards for mAbs
Currently, licensed monoclonal antibody (mAb) therapeutics include those involved in the activation of effector cells, cell killing, cross-linked induced apoptosis, antagonis…
Article
Leveraging Computational Models of Glycosylation for Biopharma QA
Man5 may also enhance antibody-dependent cellular cytotoxicity (ADCC) (8), a mechanism that improves the oncolytic activity of mAbs.
• Tandem α-1,3 galactose is a non-human glycosylation motif tha…
Article
ADC Development Robust Despite Lackluster Performance
The ADC construct combines a targeted monoclonal antibody (mAb) with a cytotoxic agent, linked together with a stable linker technology. An ADC enables the specific delivery of chemotherapeutics to tu…
Article
Re-use of Protein A Resin: Fouling and Economics
…matography has remained the de facto capture step for purification of monoclonal antibody products (mAbs). Protein A is of Staphylococcal origin and is expressed as a type I membrane protein in the b…
Article
Next Generation Process Chromatography
This is true for monoclonal antibodies (mAbs) that present the modern age in terms of fighting diseases such as cancer and autoimmune conditions. It is also true for gene therapies, which could be con…
Article
A Look at the Affinity Chromatography Landscape
…tability (up to 1 molar sodium hydroxide) and increased binding capacity for monoclonal antibodies (mAbs). It also has the ability to bind molecules with a certain variant of the VH3 domain and thus …
Article
Development of Purification for Challenging Fc-Fusion Proteins
In response, titers for monoclonal antibodies (mAbs) and Fc-fusion proteins have significantly increased (1-5).
Particularly for Fc-fusion proteins, these improvements have resulted in a …
Article
Development and Future of Protein A Chromatography Technology: Q&A with Jonathan Royce, Business Leader Chromatography Resins, Cytiva
Several years ago, we started a development project to design and validate the next-generation protein A resin, MabSelect PrismA, which was just introduced to the market. Now, 1M NaOH can in fact be u…
Article
Process Chromatography Selection for Downstream Processing Applications
Separation Technologies
BioPharm: What are the most commonly used separation technologies for biologics that are not monoclonal antibodies (mAbs)?
Björkman (Cytiva): If one excludes mAbs, then…